{
    "id": 17226,
    "cites": 27,
    "cited_by": 12,
    "reference": [
        "Appelt, S. 2009. Early entry and trademark protection  an empirical examination of barriers to generic entry. Paper presented at the Summer Conference 2009, Copenhagen Business School.",
        "Berndt, E.R., Aitken, M.L. 2010. Brand loyalty, generic entry and price competition in pharmaceuticals in the quarter century after the 1984 Waxman-Hatch Legislation. NBER Working Paper No. 16431.",
        "Bresnahan, T.F., Reiss, P.C., 1991. Entry and competition in concentrated markets. Journal of Political Economy 99, 977-1009.",
        "Danzon, P.M., Furukawa, M.F., 2008. International prices and availability of pharmaceuticals in 2005. Health Affairs 27, 221-233.",
        "Danzon, P.M., Mulcahy, A.and Towse, A.2011. Pharmaceutical pricing in emerging markets: effects of income, competition and procurement. NBER Working Paper.",
        "Ellison, G., Ellison, S.F., 2011. Strategic entry deterrence and the behavior of pharmaceutical incumbents prior to patent expiration. American Economic Journal: Microeconomics 3, 1-36.",
        "Frank, R.G., Salkever, D.S., 1992. Pricing, patent loss and the market for pharmaceuticals. Southern Economic Journal 59, 165-179.",
        "Frank, R.G., Salkever, D.S., 1997. Generic entry and the pricing of pharmaceuticals. Journal of Economics & Management Strategy 6, 75-90.",
        "Garattini, L., Ghislandi, S., 2006. Off-patent drugs in Italy: a short-sighted view? European Journal of Health Economics 7, 79-83.",
        "Ghislandi S, Krulichova I, Garattini L. Pharmaceutical policy in Italy: Towards a structural change? Health Policy 2005; 72: 53-63.",
        "Grabowski, H., Kyle, M., 2007. Generic competition and market exclusivity periods in pharmaceuticals. Managerial and Decision Economics 28, 491502.",
        "Grabowski, H., Vernon, J.M., 1992. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. Journal of Law & Economics 35, 331-350.",
        "Grabowski, H., Vernon, J., 1996. Longer Patents for increased generic competition in the U.S.: The Waxman-Hatch Act after one decade. Pharmacoeconomics 10, 110-123.",
        "Hollis, A., 2003. The anti-competitive effects of brand-controlled pseudogenerics  in the Canadian pharmaceutical market. Canadian Public Policy/Analyse de Politiques 29, 21-32.",
        "Hudson, J., 2000. Generic take-up in the pharmaceutical market following patent expiry: a multi-country study. International Review of Law and Economics 20, 205-221.",
        "Kanavos, P., Costa-Font, J., Seeley, E., 2008. Competition in off-patent drug markets: issues, regulation and evidence. Economic Policy 23, 499-544.",
        "Magazzini, L., Pammoli, F., Riccaboni, M., 2004. Dynamic competition in pharmaceuticals: patent expiry, generic penetration and industry structure. European Journal of Health Economics 5, 175-182.",
        "Moreno-Torres, I., Puig-Junoy, J., Borrell, J.R., 2009. Generic entry into the regulated Spanish pharmaceutical market. Review of Industrial Organization 34, 373388.",
        "Pammoli, F., Magazzini, L., Orsenigo, L., 2002. The intensity of competition after patent expiry in pharmaceuticals: a cross-country analysis. Revue D'Economie Industrielle 99, 107-131.",
        "Puig-Junoy, J. 2010. The impact of European pharmaceutical price regulation on price competition: a review. Pharmacoeconomics 28: 649-663.",
        "Regan, T. 2008. Generic entry, price competition, and market segmentation in the prescription drug market. International Journal of Industrial Organization (4):930-948.",
        "Reiffen, D., Ward, M.E., 2005. Generic drug industry dynamics. Review of Economics and Statistics 87, 37-49.",
        "Saha, A., Grabowski, H., Birnbaum, H., Greenberg, P., Bizan, O., 2006. Generic competition in the U.S. pharmaceutical industry. International Journal of the Economics of Business 13, 15-38.",
        "Scott Morton, F., 1999. Entry decisions in the generic pharmaceutical industry. RAND Journal of Economics 30, 421-440.",
        "Scott Morton, F., 2000. Barriers to entry, brand advertising, and generic entry in the U.S. pharmaceutical industry. International Journal of Industrial Organization 18, 1085-1104.",
        "Stargardt, T. 2010. The impact of reference pricing on switching behaviour and healthcare utilization: the case of statins in Germany. European Journal of Health Economics 11:267-277.",
        "U.S. Congressional Budget Office, 2005. Prices for brand-name drugs under selected federal programs. Washington D.C.: Congressional Budget Office."
    ]
}